Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Myelitis, Transverse × ublituximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7 Lymphoma, Follicular 2 Optic Neuritis 1 Neuromyelitis Optica 1 Myelitis, Transverse 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Disease Progression 1

Interventions

eculizumab 3 ublituximab 1 LFB-R603 1 Interferon beta-1a 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed

6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡